Clinical Trial Update: Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A sequential Phase 1/2 clinical trial of 225Ac-LNC1011 for metastatic castration-resistant prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 225Ac-LNC1011

Snippet

Sponsor: First Affiliated Hospital of Fujian Medical University | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: RECRUITING